Dec 31 (Reuters) - Kazia Therapeutics Ltd KZIA.O:
KAZIA THERAPEUTICS PROVIDES UPDATE ON PAXALISIB REGULATORY PATHWAY FOLLOWING TYPE C MEETING WITH FDA
KAZIA THERAPEUTICS LTD - FDA SAYS OS DATA NOT APPROPRIATE FOR ACCELERATED APPROVAL
KAZIA THERAPEUTICS LTD - FDA COMMENTS OS DATA SUPPORTIVE FOR PIVOTAL REGISTRATIONAL STUDY
KAZIA THERAPEUTICS LTD - ALIGNS WITH FDA ON PHASE 3 STUDY DESIGN
Source text: ID:nPn5mLr4Da
Further company coverage: KZIA.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。